Another drug, epirubicin, was found to enhance RKIP in breast cancer models by acting through NME1 (non-metastatic cells 1) which is a transcriptional activator of RKIP leading to reduced cell migratory capabilities [210]. This evidence concerns the gene PEBP1 and breast carcinoma.